basiliximab + mycophenolate mofetil + cyclosporine + prednisone

This is a **combination immunosuppressive regimen** consisting of basiliximab, mycophenolate mofetil, cyclosporine, and prednisone. Used primarily as an induction and maintenance therapy to prevent **acute organ rejection after kidney transplantation**, this regimen combines four drugs with complementary mechanisms of action: - **Basiliximab** is a chimeric monoclonal antibody targeting the CD25 (alpha chain) of the Interleukin-2 receptor on activated T-lymphocytes, selectively inhibiting IL-2-mediated T-cell activation and proliferation, thereby reducing immune responses directed against the transplanted organ[2][4][6][8]. - **Mycophenolate mofetil** acts as a prodrug of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase, blocking purine synthesis required for lymphocyte proliferation[3][7]. - **Cyclosporine** is a calcineurin inhibitor that prevents T-cell activation by inhibiting the transcription of cytokines including interleukin-2[3][7]. - **Prednisone** is a synthetic glucocorticoid that broadly suppresses immune and inflammatory responses through multiple pathways[7]. This combination provides a multi-targeted approach to immunosuppression, improving graft survival and reducing the risk of organ rejection while minimizing the risk of adverse effects and infections by balancing the intensity of immunosuppression across several mechanisms.